Jeff Sharman, MD: MRD testing at this point is prognostic; it tells you how likely a patient is to maintain their response. But to date, there’s nothing that tells us how to change therapy based on MRD status. There are studies coming that will potentially have MRD-adapted treatment decisions. Findings from those studies have not reported. MRD testing, therefore, really just helps us to understand the likelihood of length of a response.
With patients treated with BTK strategies, MRD isn’t so much a consideration. That’s primary amongst patients treated with venetoclax. We’re asked how accurately it predicts the risk of relapse and how widely is it being used. Well, again, following obinutuzumab-venetoclax, you can check MRD status. From the MURANO Study, which is a population of relapsed-refractory patients treated with obinutuzumab-venetoclax, you can stratify based upon MRD high, low, and negative. If you’re negative, chances are you’re going to maintain your response considerably longer than those patients who are low or high. Those patients are going to have relatively short durations of response.
Transcript edited for clarity.
Case: A 79-Year-Old Man With Relapsed Chronic Lymphocytic Leukemia
Initial presentation
Clinical workup
Leslie Reviews Relevant Data for Treatment of Relapsed/Refractory CLL
May 8th 2024During a Case-Based Roundtable® event, Lori A. Leslie, MD, discussed Bruton tyrosine kinase inhibition options for a patient with relapsed/refractory chronic lymphocytic leukemia in the first article of a 2-part series.
Read More
Marks Explores Cardiac Toxicities and Dosing Concerns of BTK Inhibitors in CLL
April 26th 2024During a Case-Based Roundtable® event, Stanley M. Marks, MD, moderated a discussion on the impact of cardiac adverse events on patients who receive a Bruton tyrosine kinase inhibitor for chronic lymphocytic leukemia.
Read More
Considering the Durability of Zanubrutinib in Relapsed/Refractory CLL
April 11th 2024During a Case-Based Roundtable® event, Marc S. Hoffmann, MD, discussed his viewpoints on the use of Bruton tyrosine kinase inhibitors for patients with relapsed/refractory chronic lymphocytic leukemia and the efficacy behind zanubrutinib in the second article of a 2-part series.
Read More
Acalabrutinib/Obinutuzumab Shows Improved PFS in Treatment-Naive CLL
April 10th 2024In an interview with Targeted Oncology, Jeff Sharman, MD, discussed the results of the ELEVATE-TN trial of acalabrutinib with or without obinutuzumab at 74.5 months of follow-up among patients with chronic lymphocytic leukemia.
Read More